75907-74-3

Basic information

• Product Name: Pyrazinemethanol, 3,5,6-trimethyl- (6CI,9CI)
• Synonyms: Pyrazinemethanol, 3,5,6-trimethyl- (6CI,9CI);3,5,6-TRIMETHYL-PYRAZINEMETHANOL;(3,5,6-Trimethylpyrazin-2-yl)methanol;(3,5,6-trimethylpyrazin-2-yl)methanol(SALTDATA: FREE);2-PyrazineMethanol,3,5,6-triMethyl-
• CAS NO: 75907-74-3
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.1937
• Product Categories: PIPERIDINE
• Mol File: 75907-74-3.mol
• Article Data: 42

Chemical Properties

• Melting Point: 65 °C
• Boiling Point: 257.778 °C at 760 mmHg
• Flash Point: 109.701 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.81±0.10(Predicted)
• CAS DataBase Reference: Pyrazinemethanol, 3,5,6-trimethyl- (6CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazinemethanol, 3,5,6-trimethyl- (6CI,9CI)(75907-74-3)
• EPA Substance Registry System: Pyrazinemethanol, 3,5,6-trimethyl- (6CI,9CI)(75907-74-3)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 75907-74-3(Hazardous Substances Data)

Usage

General Description

Pyrazinemethanol, 3,5,6-trimethyl- (6CI,9CI) is a chemical compound with the molecular formula C8H12N2O. It is a colorless liquid with a faint odor, and it is commonly used in the production of pharmaceuticals and other organic compounds. This chemical is also known for its potential use as a solvent and in the synthesis of other chemicals. Pyrazinemethanol, 3,5,6-trimethyl- (6CI,9CI) is considered to have low toxicity, but proper safety precautions should still be taken when handling this substance. Its precise role and applications may vary depending on the specific industry and application.

InChI:InChI=1/C8H12N2O/c1-5-6(2)10-8(4-11)7(3)9-5/h11H,4H2,1-3H3

Upstream product

• 22978-83-2 2,3,5,6-tetramethylpyrazine mono N-oxide 
• 76494-51-4 2,3,5,6-tetramethylpyrazine hydrochloride 
• 123624-93-1 Trimethyl<(3,5,6-trimethyl-2-pyrazinyl)methyl>ammonium chloride 
• 123624-90-8 2-(chloromethyl)-3,5,6-trimethylpyrazine 
• 1124-11-4 Tetramethylpyrazine 
• 79074-43-4 (3,5,6-trimethylpyrazin-2-yl)methyl acetate 
• 857185-16-1 2,5-Dihydro-2,5-dimethylenepyrazine 

Downstream Products

• 123624-90-8 2-(chloromethyl)-3,5,6-trimethylpyrazine 
• 186534-02-1 3,5,6-trimethyl-pyrazine-2-carbaldehyde 
• 186534-01-0 3,5,6-trimethylpyrazine-2-carboxylic acid 
• 1332730-39-8 methyl 3,5,6-trimethylpyrazine-2-carboxylate 
• 1354824-57-9 C₁₆H₂₂N₄O 
• 1400563-37-2 (3,5,6-trimethylpyrazin-2-yl)methyl 3-methylbutanoate 
• 1400563-38-3 (S)-(3,5,6-trimethylpyrazin-2-yl)methyl 2-methylbutanoate 
• 1128045-85-1 2-phenyl-N-((3,5,6-trimethylpyrazin-2-yl)methyl)acetamide 
• 1128045-87-3 3-chloro-N-((3,5,6-trimethylpyrazin-2-yl)methyl)benzamide 
• 1128045-89-5 N-((3,5,6-trimethylpyrazin-2-yl)methyl)nicotinamide 
• 1128045-91-9 2-(((3,5,6-trimethylpyrazin-2-yl)methyl)carbamoyl)phenyl acetate 
• 1128046-20-7 2-hydroxy-N-((3,5,6-trimethylpyrazin-2-yl)methyl)benzamide 

Relevant articles and documents

Novel ligustrazine derivative as well as preparation method and application thereof

The invention provides a novel ligustrazine derivative as well as a preparation method and application thereof. Experiments prove that the ligustrazine derivative can effectively protect nerve cells and myocardial cells from CoCl2 hypoxia injury; and meanwhile, the ligustrazine derivative has the effect of remarkably inhibiting platelet aggregation. Therefore, the ligustrazine derivative disclosed by the invention can be used for preparing medicines for effectively preventing or treating central nervous system diseases and/or thrombotic diseases; more importantly, the effect of the ligustrazine derivative is obviously superior to that of ligustrazine with the same dosage. The invention widens the new application of the novel ligustrazine derivative, and has huge economic and social values.

Pyrazine compound and preparation method thereof

The invention relates to a pyrazine compound, a stereoisomer, a tautomer and a pharmaceutically acceptable salt thereof, wherein the pyrazine compound, the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof can treat Alzheimer's disease, Parkinson's disease, Huntington's disease, frontal temporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis,progressive spinal cord lateral sclerosis, Friedel-Crafts ataxia, neuropathic pain or glaucoma and other neurodegenerative diseases, diabetes mellitus and related diabetic complications, inflammations, oxidative damage and mitochondria-related diseases.

Discovery of a new tetramethylpyrazine based chalcone with α, β-unsaturated ketone moiety as a potential anticancer agent

In this study, a new ligustrazine-based chalcone molecule has been synthesized that contains an extra α, β-Unsaturated ketone moiety along with α, the β-Unsaturated carbonyl group of chalone. A new tetramethylpyrazine (TMP) based aldehyde was synthesized to make the TMP (ligustrazine) as part of chalcone and then it was reacted with newly synthesized ketone containing additional α, β-Unsaturated ketone moiety. After characterization, this new compound was evaluated for its effect on different types of cancer cell lines and very promising results were obtained. The growth of these cancer cells was inhibited by newly designed and synthesized compounds, especially for colon and pancreatic cancer cells with IC50 0.04-0.05 μM.